Live attenuated Salmonella Typhimurium with monophosphoryl lipid A retains ability to induce T-cell and humoral immune responses against heterologous polysaccharide of Shigella flexneri 2a

Liu, Qing; Su, Huali; Bian, Xiaoping; Wang, Shifeng; Kong, Qingke

doi:10.1016/j.ijmm.2020.151427

Cited by 6 publications

(4 citation statements)

References 58 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Live attenuated Salmonella Typhimurium has been developed as a mature delivery vector. As live oral vaccines, there has been meaningful progress in antibacterial [ 29 , 35 ], antiviral [ 36 ], antiparasitic [ 37 , 38 ], and antitumor [ 39 ] research. Though with good features as delivery vaccines, live attenuated Salmonella Typhimurium strains remain potential side effects.…”

Section: Discussionmentioning

confidence: 99%

Oral Administration with Recombinant Attenuated Regulated Delayed Lysis Salmonella Vaccines Protecting against Staphylococcus aureus Kidney Abscess Formation

et al. 2022

View full text Add to dashboard Cite

Abscess formation is one of the main symptoms of Staphylococcus aureus infection. It is very important to inhibit abscess formation for preventing S. aureus persistent infection. To find a feasible solution, the live oral vaccines delivering S. aureus antigens, rEsxAB and rHlam, were constructed, which were based on the attenuated regulated delayed lysis Salmonella enterica subspecies Serovar Typhimurium strain χ11802, and the inhibiting effect on abscess formation was evaluated in mice kidneys. As the results showed, after oral administration, humoral immunity was induced via the mucosal route as the antigen-specific IgG in the serum and IgA in the intestinal mucus both showed significant increases. Meanwhile, the production of IFN-γ and IL-17 in the kidney tissue suggested that Th1/Th17-biased cellular immunity played a role in varying degrees. After challenged intravenously (i.v.) with S. aureus USA300, the χ11802(pYA3681−esxAB)-vaccinated group showed obvious inhibition in kidney abscess formation among the vaccinated group, as the kidney abscess incidence rate and the staphylococcal load significantly reduced, and the kidney pathological injury was improved significantly. In conclusion, this study provided experimental data and showed great potential for live oral vaccine development with the attenuated regulated delayed lysis Salmonella Typhimurium strains against S. aureus infection.

show abstract

Section: Discussionmentioning

confidence: 99%

Oral Administration with Recombinant Attenuated Regulated Delayed Lysis Salmonella Vaccines Protecting against Staphylococcus aureus Kidney Abscess Formation

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Because they are versatile and reliably induce Th1-biased immune responses, live attenuated oral Salmonella vaccine strains are widely used in agriculture, veterinary medicine, and preventative care of humans to protect against salmonellosis (11, 12), typhoid (13, 14) and paratyphoid fever (15). The recombinant attenuated oral Salmonella vaccine (RASV) system has also been used as an experimental vaccine platform to develop oral vaccine candidates for protection against food borne parasites (56, 57), human papilloma virus (58), streptococcal pneumonia (55), and shigellosis (59), among many other pathogens. Yet, disparities in the immunogenicity of oral Salmonella vaccines (60, 61) and other oral and parenteral vaccines in low- and middle-income countries compared to high-income countries have been repeatedly described (62–65).…”

Section: Discussionmentioning

confidence: 99%

Intestinal helminth infection impairs oral and parenteral vaccine efficacy

Hardy

Kapita²,

Campbell

et al. 2022

Preprint

View full text Add to dashboard Cite

The impact of endemic parasitic infection on vaccine efficacy is an important consideration for vaccine development and deployment. We have examined whether intestinal infection with the natural murine helminth Heligmosomoides polygyrus bakeri alters antigen-specific antibody and cellular immune responses to oral and parenteral vaccination in mice. We found that oral vaccination of mice with a clinically relevant, live, attenuated, recombinant Salmonella vaccine that expresses chicken egg ovalbumin (Salmonella-OVA) disrupts ovalbumin-specific regulatory T cell networks in the gut associated lymphoid tissue and promotes T-effector responses to OVA. Chronic intestinal helminth infection significantly reduced Th1-skewed antibody responses to oral vaccination with Salmonella-OVA. Activated, adoptively-transferred, OVA-specific CD4+ T cells accumulated in draining mesenteric lymph nodes (MLN) of vaccinated mice, irrespective of their helminth-infection status. However, helminth infection increased the frequencies of adoptively-transferred OVA-specific CD4+ T cells producing IL-4 and IL-10 in the MLN. Chronic intestinal helminth infection also significantly reduced Th2-skewed antibody responses to parenteral vaccination with OVA adsorbed to alum. These findings suggest helminth-induced impairment of vaccine antibody responses may be driven by the development of IL-10-secreting CD4+ T regulatory cells. They also underscore the potential need to treat parasitic infection before mass vaccination campaigns in helminth-endemic areas.

show abstract

“…Controlled by the LacI-repressible P trc promoter, this platform could be induced to synthesize native Salmonella LPS in the presence of arabinose and triggered Sf2a O-antigen synthesis in the absence of arabinose, demonstrating its potential for effective vaccines against Shigella and Salmonella infections [97]. A RASV-delivered Sf2a, O-antigen can induce robust CD4+ T-cell responses and IgG responses, thereby warranting further research to develop Shigella vaccine candidates using RASV [98]. Furthermore, an oral Shigella 2aT32-based vaccine expressing a fusion antigen of UreB-HspA, which were important vaccine candidate antigens for Helicobacter pylori, has been evaluated as a potential vaccine against both Shigella and H. pylori in a mouse model [99].…”

Section: Shigella Live Attenuated Vaccines (Lavs)mentioning

confidence: 99%

Shigella Vaccines: The Continuing Unmet Challenge

Lu,

Das,

Howlader

et al. 2024

IJMS

View full text Add to dashboard Cite

Shigellosis is a severe gastrointestinal disease that annually affects approximately 270 million individuals globally. It has particularly high morbidity and mortality in low-income regions; however, it is not confined to these regions and occurs in high-income nations when conditions allow. The ill effects of shigellosis are at their highest in children ages 2 to 5, with survivors often exhibiting impaired growth due to infection-induced malnutrition. The escalating threat of antibiotic resistance further amplifies shigellosis as a serious public health concern. This review explores Shigella pathology, with a primary focus on the status of Shigella vaccine candidates. These candidates include killed whole-cells, live attenuated organisms, LPS-based, and subunit vaccines. The strengths and weaknesses of each vaccination strategy are considered. The discussion includes potential Shigella immunogens, such as LPS, conserved T3SS proteins, outer membrane proteins, diverse animal models used in Shigella vaccine research, and innovative vaccine development approaches. Additionally, this review addresses ongoing challenges that necessitate action toward advancing effective Shigella prevention and control measures.

show abstract

Live attenuated Salmonella Typhimurium with monophosphoryl lipid A retains ability to induce T-cell and humoral immune responses against heterologous polysaccharide of Shigella flexneri 2a

Cited by 6 publications

References 58 publications

Oral Administration with Recombinant Attenuated Regulated Delayed Lysis Salmonella Vaccines Protecting against Staphylococcus aureus Kidney Abscess Formation

Oral Administration with Recombinant Attenuated Regulated Delayed Lysis Salmonella Vaccines Protecting against Staphylococcus aureus Kidney Abscess Formation

Intestinal helminth infection impairs oral and parenteral vaccine efficacy

Shigella Vaccines: The Continuing Unmet Challenge

Contact Info

Product

Resources

About